Glioblastoma multiforme

16 trials 8 recruiting MedDRA PT
16 Registered trials
8 Recruiting
12 Unique sponsors
10 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
L Oncology (ATC L) 4
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Alkylating agent 1 substance
Antimetabolite 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 3 Phase I/II: 1 Phase I (Other): 7 Phase I (First in Human): 3

Filter these 16 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 16 trials

Phase III

1 trial
  • Centre Oscar Lambret Academic
    IMP not specified
    2022-500451-23-00 2 countries 2019 n=460
    Ended

Phase II/III

1 trial
  • Oslo University Hospital HF Academic
    TEMOZOLOMIDE
    2024-518663-35-00 1 country 2018 n=60
    Recruiting

Phase II

3 trials
  • Cns Pharmaceuticals Inc. Commercial
    BERUBICIN HYDROCHLORIDE; LOMUSTINE
    2024-517660-27-00 3 countries 2022 n=126
    Ended
  • Karolinska Institutet Academic
    IMP not specified
    2023-504846-73-01 2 countries n=220
    Pending
  • Turku University Hospital Academic
    LSTA1; TEMOZOLOMIDE
    2023-506813-23-00 3 countries 2023 n=40
    Recruiting

Phase I/II

1 trial
  • Genenta Science S.p.A. Commercial
    AUTOLOGOUS CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING THE INTERFERON ALPHA-2 GENE
    2024-516211-25-00 1 country 2022 n=5 Orphan
    Recruiting

Phase I (Other)

7 trials
  • Curasight A/S Commercial
    IMP not specified
    2024-520105-39-00 1 country 2025 n=6
    Recruiting
  • Telix Pharmaceuticals (Innovations) Pty Limited Commercial
    IMP not specified
    2024-515466-13-00 2 countries 2023 n=9
    Recruiting
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic
    IMP not specified
    2023-505743-38-00 1 country 2024 n=18
    Ended
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic
    IMP not specified
    2025-523340-12-00 1 country n=18
    Pending
  • Oslo University Hospital HF Academic
    GEMCITABINE
    2023-510214-11-00 1 country 2023 n=15
    Recruiting
  • Region Midtjylland Academic
    IMP not specified
    2025-522605-37-00 1 country 2026 n=36
    Recruiting
  • UZ Brussel Academic
    CD1C+/CD141+ MYELOID DENDRITIC CELLS ISOLATED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB
    2024-517842-33-01 1 country 2024 n=113
    Recruiting

Phase I (First in Human)

3 trials
  • Genenta Science S.p.A. Commercial
    IMP not specified
    2023-510299-29-00 1 country 2019 n=27
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502367-37-00 3 countries 2024 n=55
    Ended
  • UZ Brussel Academic
    IMP not specified
    2023-508278-26-01 1 country 2024 n=18
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Genenta Science S.p.A. Commercial 2 Phase I (First in Human), Phase I/II 1
Oslo University Hospital HF Academic 2 Phase II/III, Phase I (Other) 2
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic 2 Phase I (Other) 0
UZ Brussel Academic 2 Phase I (Other), Phase I (First in Human) 1
Curasight A/S Commercial 1 Phase I (Other) 1
Telix Pharmaceuticals (Innovations) Pty Limited Commercial 1 Phase I (Other) 1
Cns Pharmaceuticals Inc. Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
Region Midtjylland Academic 1 Phase I (Other) 1
Karolinska Institutet Academic 1 Phase II 0
Turku University Hospital Academic 1 Phase II 1
Centre Oscar Lambret Academic 1 Phase III 0
New trials by year
2019
2
2022
2
2023
3
2024
4
2025
1
2026
1
← All indication landscapes